Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | baculoviral IAP repeat containing protein | 0.0614 | 0.0099 | 0.0099 |
Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0614 | 0.0099 | 0.0263 |
Leishmania major | 0.0491 | 0 | 0.5 | |
Echinococcus multilocularis | sodium calcium exchanger | 1.2865 | 1 | 1 |
Schistosoma mansoni | sodium/calcium exchanger | 1.2865 | 1 | 1 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.2269 | 0.1437 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0614 | 0.0099 | 0.0099 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0491 | 0 | 0.5 |
Echinococcus multilocularis | inhibitor of apoptosis protein | 0.0614 | 0.0099 | 0.0099 |
Schistosoma mansoni | inhibitor of apoptosis protein | 0.0614 | 0.0099 | 0.0099 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.2269 | 0.1437 | 0.5 |
Brugia malayi | Sodium/calcium exchanger protein | 0.5146 | 0.3762 | 1 |
Loa Loa (eye worm) | solute carrier family 8 | 1.2865 | 1 | 1 |
Onchocerca volvulus | Deterin homolog | 0.0614 | 0.0099 | 0.5 |
Toxoplasma gondii | fructose-bisphospatase II | 0.0491 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0614 | 0.0099 | 0.0099 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0491 | 0 | 0.5 |
Echinococcus multilocularis | baculoviral IAP repeat containing protein | 0.0614 | 0.0099 | 0.0099 |
Loa Loa (eye worm) | hypothetical protein | 0.0614 | 0.0099 | 0.0099 |
Schistosoma mansoni | inhibitor of apoptosis (iap) domain family member | 0.0614 | 0.0099 | 0.0099 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0491 | 0 | 0.5 |
Onchocerca volvulus | 0.0614 | 0.0099 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.5146 | 0.3762 | 0.3762 |
Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0614 | 0.0099 | 0.0263 |
Echinococcus granulosus | inhibitor of apoptosis protein | 0.0614 | 0.0099 | 0.0099 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.